loader2
Login Open ICICI 3-in-1 Account

Alembic Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Alembic Pharmaceuticals Ltd. 04 Nov 2025 14:48 PM

Q2FY26 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.

Pharmaceuticals company Alembic Pharmaceuticals announced Q2FY26 results

  • Revenue from operations increased by 16% to Rs 1,910 crore
  • EBITDA increased by 26% to Rs 325 crore
  • EBITDA Margin at 17% of revenue.
  • Reported Profit After Tax at Rs 185 crore up by 20%.

Shaunak Amin MD, Alembic Pharmaceuticals, said: "Our Q2 performance reflects continued momentum in our core businesses and the disciplined execution. We have strengthened our presence across key markets while maintaining a sharp focus on profitability and operational excellence, delivering an overall growth of 16% and pre-R&D EBITDA margin of 26%. Our R&D investment, at around 10% of revenue, reflects our commitment to building a strong pipeline for future growth. We continue to focus on complex and high-value areas such as injectables, peptides, oral solids, and drug discovery. During the quarter, we completed the acquisition of Utility Therapeutics that provides a segway in to branded drugs in the US."

Result PDF

Pharmaceuticals company Alembic Pharmaceuticals announced Q1FY26 results

  • Revenue increased by 10% to Rs 1,711 crore.
  • EBITDA up by 20% to Rs 288 crore.
  • EBITDA Margin at 17%.
  • Profit Before Tax up by 21% to Rs 191 crore.
  • Net Profit at Rs 154 crore up by 15%.

Pranav Amin MD, Alembic Pharmaceuticals, said: We began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we ramp up utilization of our new manufacturing facilities and continue to drive cost optimization initiatives, we expect to benefit from improved operating leverage.

Result PDF

Pharmaceuticals company Alembic Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Net Sales increased by 17% to Rs.1770 crore
  • EBITDA up by 9% to Rs. 286 crore
  • EBITDA Margin at 16% of Sales
  • Profit Before Tax up by 5% to Rs.192 crore
  • Net Profit at Rs.157 crore

FY25 Financial Highlights:

  • Revenue from operations stood at 6672 crore for FY25 compared to 6228 crore for FY24
  • Net profit stands at 583 crore for FY25 compared to compared to 615 crore for FY24

Shaunak Amin, MD, Alembic Pharmaceuticals, said, “India-Branded Business displayed improved performance, backed by Specialty therapies. While the Animal Health division continued to outperform through a strong portfolio of trusted brands. By deepening our engagement with healthcare professionals and expanding our product pipeline, we have laid a solid foundation for strong, consistent growth, going forward. Our Ex-US business delivered a strong growth of 43% across all markets whereas the US business grew by 20% during the quarter.”

Result PDF

Pharmaceuticals company Alembic Pharmaceuticals announced Q3FY25 results

  • Net Sales increased by 4% to Rs 1693 crore.
  • EBITDA up 1% to Rs 271 crore.
  • EBITDA Margin at 16% of Sales.
  • Net Profit at Rs 138 crore.

Shaunak Amin, MD, Alembic Pharmaceuticals, said: "In the current quarter, we faced market headwinds in the acute segment. However, other key therapies in our specialty business continued to outpace the market growth. To strengthen field force efficiency, we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter growth. We are confident to show a robust growth trajectory going forward. The US Business posted significant volume growth and the Ex-US markets continued to expand steadily. API Business is still under significant pricing pressure.”

Result PDF

Pharmaceuticals company Alembic Pharmaceuticals announced Q2FY25 results

Financial Highlights:

  • Net Sales increased by 3% to Rs.1648 crore.
  • EBITDA up 18% to Rs 257 crore.
  • EBITDA Margin at 15.6% of Sales.
  • Net Profit up 12% to Rs.153 crore.

Other Highlights:

  • India Branded Business:
    • India Branded Business grew 6% to Rs 609 crore for the quarter.
    • Recorded good growths in specialty therapies like 8% in Gynaecology, 11% in Cardiology, 18% in Anti Diabetic and 13% in Ophthalmology therapies.
    • Animal Health business grew 20% for the quarter with basket of strong brands driving outperformance.
    • 3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.
  • International Business:
    • US Generics grew 5% to Rs 467 crore for the quarter.
    • 8 Launches in the US market during the quarter.
    • Ex-US International Formulations grew 18% to Rs 298 crore for the quarter.
    • 9 ANDA approvals received during the quarter, 214 Cumulative ANDA approvals.
  • API Business:
    • API business at Rs 274 crore for the quarter

Shaunak Amin, MD, Alembic Pharmaceuticals, said: "India’s Branded Business continues to enhance execution capabilities in both quality and scale, with the Specialty and Animal Health segments showing good growth. The USFDA successfully inspected our Oncology Formulation Facility (F-2) without any form 483 observations.”

Result PDF

Pharmaceuticals company Alembic Pharmaceuticals announced Q1FY25 results:

Financial Highlights: 

  • Net Sales increased 5% to Rs 1,562 crore.
  • Net Profit up 12% to Rs 135 crore.
  • EBITDA up 14% to Rs 239 crore.

Operational Highlights:

  • India Branded Business grew 9% to Rs 572 crore for the quarter.
  • Recorded robust growths in specialty therapies like Gynecology, Gastrointestinal,
  • Anti Diabetic and Ophthalmology therapies and performed relatively better than the market in acute therapies.
  • Excess heat waves in Q1FY25 lead to unnatural market disturbances in affected geographies.
  • Animal Health business grew 23% for the quarter with basket of strong brands driving outperformance.
  • New launches continue to do well along with promising future launches across key segments. 
  • US Generics grew 18% to Rs 461 crore for the quarter.
  • 2 Launches in the US market during the quarter.
  • Ex-US International Formulations grew 2% to Rs 271 crore for the quarter.
  • 206 Cumulative ANDA approvals.
  • API business at Rs 259 crore for the quarter.

Shaunak Amin, MD, Alembic Pharmaceuticals Limited said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth.

The USFDA conducted an audit at our Formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18% during the quarter"

Result PDF

Pharmaceuticals company Alembic Pharmaceuticals announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Net Sales increased 8% to Rs 1,517 crore.
  • Net Profit up 17% to Rs 178 crore
  • EBITDA up 29% to Rs 263 crore

FY24 Financial Highlights:

  • Net Sales grew 10% to Rs 6,229 crore.
  • Net Profit up 80% to Rs 616 crore
  • EBITDA up 41% to Rs 961 crore. 

Shaunak Amin, MD, Alembic Pharmaceuticals said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth. The outlook for the US business appears better, with the commercialization of new facilities and launches set to scale up along with continued progress in achieving cost improvements. The Ex-US generics and the API business maintained a steady continuous growth.”

Result PDF

Alembic Pharmaceuticals announced Q3FY24 results:

Financial Summary:
- Net Sales: Increased to Rs 1,631 crore in Q3FY24, marking an 8% growth compared to Q3FY23.
- Net Profit: Rose by 48% to Rs 180 crore from Rs 122 crore in Q3FY23.
- EBITDA: Grew 14% to Rs 269 crore in Q3FY24.

Operational Highlights:
India Branded Business:
- Reported sales of Rs 596 crore, up by 9% for the quarter.
- Observed strong performance in Gynecology, Gastrointestinal, Anti Diabetic, and Ophthalmology therapies.
- Antibiotic and Respiratory segments continued better performance trends compared to the market.

Animal Health Business:
- Achieved a growth of 32% YoY.

International Business:
- US Generics: Saw a 9% increase to Rs 474 crore for the quarter.
- Ex-US International Formulations: Recorded a 32% growth, amounting to Rs 272 crore for the quarter.
- Received 7 ANDA approvals, reaching a total of 196 cumulative approvals.

API Business:
- Posted revenues of Rs 289 crore for the quarter.

Shaunak Amin, MD, Alembic Pharmaceuticals said, “The India Branded Business was underpinned by a continued incremental improvement in core operations. The Specialty and Animal health segments continued their strong outperformance; whereas the Acute performance was relatively satisfactory despite challenging market conditions. The Ex US generics grew 32% in the quarter, whereas the US returned to a 9% growth on the back of 11 launches and 7 approvals.”

 

 

Result PDF

Alembic Pharmaceuticals announced Q2FY24 & H1FY24 results:

1. Financial Highlights:
- Net Sales grew 8% to Rs 1,595 crore for Q2FY24.
- Net Profit for the quarter at Rs 137 crore.
- Net Sales grew 13% to Rs 3,081 crore for the H1FY24.
- Net Profit for H1FY24 at Rs 257 crore.

2. India Branded Business:
- India Branded Business at Rs 577 crore witnessed growth of 5% in Q2FY24 against IPM growth of 7%.
- Specialty therapies recorded growth of 10% vis a vis industry growth of 9%.
- Performed relatively better than the market in the Antibiotic and Respiratory segments.
- Animal Health business recorded growth of 32% over Q2FY23.

3. International Business:
- US Generics at Rs 444 crore up by 6% on a YoY basis and by 14% on a QoQ basis.
- Ex-US International Formulations grew 17% to Rs 252 crore in the quarter.
- Regular exports from both general injectable and oncology plants.

4. API Business:
- API business grew 10% at Rs 322 crore in the quarter.
- 132 cumulative DMF Filings.

Shaunak Amin, Managing Director, Alembic Pharmaceuticals, said, "Despite the challenges of a muted demand in the Antibiotic and respiratory market, it was a satisfactory quarter, backed with a strong performance by our specialty and animal healthcare portfolio. We are confident of returning to an industry-beating growth moving forward."

Pranav Amin, Managing Director, Alembic Pharmaceuticals, said, "It was a satisfactory quarter led by growth in all the verticals of the company, in particular Ex-US which grew by 17% and the API business outperformed with a 10% growth during the quarter."

 

 

Result PDF

Alembic Pharmaceuticals announced Q1FY24 results:

  • Net Sales grew 18% to Rs 1,486 crore for Q1FY24.
  • Net Profit for Q1FY24 at Rs 121 crore.

Pranav Amin, Managing Director, Alembic Pharmaceuticals said, “The company grew in all the business segments with India outperforming the market with 9% growth, Ex-US generics grew 46%, API grew 31% and the US generics business grew 6%. We have also started commercializing products from our Oncology and Injectable facilities”

 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app